Financial Performance - The company achieved encouraging performance in the fiscal year 2021 despite the disruptions caused by the COVID-19 pandemic[11]. - The company reported a revenue of approximately 654.7 million HKD for the fiscal year 2021, an increase of about 44.3% compared to 453.7 million HKD in the fiscal year 2020[22]. - The company recorded a profit of approximately HKD 144.5 million in FY2021, a significant increase of about HKD 184.8 million compared to a loss of approximately HKD 40.4 million in FY2020, resulting in a net profit margin improvement from -8.9% to 22.1%[39]. - Total revenue for FY2021 was approximately HKD 654.7 million, representing an increase of about 44.3% compared to FY2020[42]. - The company reported a significant increase in revenue, achieving a total of HKD 1.2 billion for the fiscal year 2021, representing a growth of 15% compared to the previous year[123]. Revenue Sources and Growth - Revenue from primary healthcare services increased by approximately 202.4 million HKD or 76.0% to about 469.0 million HKD in fiscal year 2021, driven by the expansion of services related to prevention, testing, vaccination, and outreach[23]. - The revenue from primary healthcare services increased by approximately 76.0% from HKD 266.5 million in FY2020 to HKD 469.0 million in FY2021[51]. - New product launches are expected to contribute an additional HKD 200 million in revenue, with a focus on innovative healthcare solutions[103]. - The company is expanding its market presence in D regions, aiming to capture a larger share of the healthcare market[115]. Cost Management and Expenses - The management implemented cost control measures, including short-term cost reduction strategies and long-term cost structure optimization[13]. - The cost of services provided increased by approximately 14.1 million HKD or 5.4% to about 278.0 million HKD in fiscal year 2021, primarily due to increases in direct costs and pharmaceutical costs[26]. - Administrative expenses rose by approximately HKD 22.2 million or 10.7% from about HKD 208.4 million in FY2020 to approximately HKD 230.6 million in FY2021, mainly due to increased trade receivables impairment and higher wages[33]. - The company has implemented cost-saving measures, resulting in a reduction of operational expenses by G%[119]. Strategic Initiatives and Services Expansion - The company expanded its primary care services to include pandemic-related services such as prevention, testing, vaccination, and outreach services[13]. - The company launched its own online shopping platform to meet the growing demand for health and pandemic-related products and services[13]. - The company plans to introduce booster vaccinations in the short term, with vaccination services potentially becoming a regular offering[15]. - The group aims to explore opportunities in various fields while maintaining its position as a market leader in providing high-quality services[22]. - The group is actively exploring and developing health-related products and services, including health check packages and vaccination services[49]. Market Outlook and Future Projections - The company anticipates a gradual decrease in overall demand for pandemic-related services as the pandemic situation eases[14]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 10% to 12% based on current market trends and user acquisition strategies[103]. - The company has outlined a future outlook with a projected revenue growth of 20% for the next fiscal year, driven by new service offerings and market expansion strategies[123]. - The board remains cautiously optimistic about business growth and financial performance for the next fiscal year, despite uncertainties related to the pandemic[65]. Corporate Governance and Management - The company is committed to adhering to corporate governance standards, ensuring transparency and accountability in its operations[130]. - The board of directors has reviewed and confirmed compliance with all applicable corporate governance codes, reinforcing the company's commitment to ethical practices[130]. - The company has established procedures for directors to seek independent advice at the company's expense when necessary[136]. - The board of directors held seven meetings in the fiscal year 2021, including reviews of annual and interim financial statements and corporate governance matters[167]. Human Resources and Talent Management - The group recognizes the importance of attracting and retaining professional talent amid rising costs due to talent shortages and competition in the healthcare sector[70]. - The group employed 450 full-time employees as of June 30, 2021, an increase from 362 in 2020, and 479 part-time employees, up from 114 in 2020[85]. - The management team emphasized the importance of maintaining high-quality medical services, with ongoing training programs for healthcare professionals[124]. Community Engagement and Health Initiatives - The company actively participated in the Hong Kong government's community testing program, providing various testing options to the public[44]. - The company is committed to providing various preventive and early screening health services to enhance public health awareness[13]. - The group has been promoting various vaccination activities through social media to meet the rising demand for services such as cervical cancer and shingles vaccines[47].
盈健医疗(01419) - 2021 - 年度财报